Portland, OR -- (SBWIRE) -- 07/21/2017 -- Natural killer cells, also known as NK cells, K cells, and killer cells, are a type of cytotoxic lymphocyte, which is a component of the innate immune system. These cells are the first line of defense and play a vital role in the host-rejection of both tumors and virally infected cells. NK cells are unique in nature and provide faster immune reactions as compared to other immune cells.

Early buyers will receive 20% customization on this report.

The global Natural Killer Cell Therapeutics Market is expected to witness significant growth during the forecast period due to factors such as increase in awareness regarding immunotherapy and technological advancements focused on the development of bispecific antibody formats engaging NK cells to kill tumor cells. Thus, bispecific antibodies particularly trigger NK cells instead of T cells which may reduce the risk of side effects, associated with T cells. Coupled with technological advancements, high prevalence of chronic diseases (such as cardiovascular diseases and cancer), and strong product pipeline is projected to garner the growth of the market. High cost and side effects caused by NK cells medication can pose as a major obstacle for the growth of natural killer cell therapeutics market.

The natural killer cell therapeutics market is analyzed based on four geographical regions, which include North America (U.S., Canada, and Mexico); Europe (France, Germany, UK. Italy, Spain, and rest of Europe); Asia-Pacific (China, India, Australia, South Korea, and rest of Asia-Pacific); and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Request for Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/2132

The natural killer cell therapeutics market is highly competitive in nature as major players focus on R&D of NK cells, and adopt collaboration as their key strategy. The major players in the natural killer cell therapeutics market include Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc. and others.